NCT04842812

Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

Engineered TILs/CAR-TILs With PD1 Knockout and Anti-PD1/CTLA4-scFv Secreting or CARs Against Various Antigens to Treat Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Second Affiliated Hospital of Guangzhou Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. The safety, tolerance, and preliminary clinical efficacy of the TILs will be evaluated.

Detailed description

1. Choose appropriate patients with advanced lung or other cancers, with written consent for this study; 2. Perform biopsy or collect cancerous effusion in thorax or abdomen to obtain TILs by standard protocol; 3. Grow TILs and engineered the tumor-effective TILs with CRISPRA-CAS9 technique to knockdown PD1 and electronic-transfection strategy to express scFvs that target PD1 and CTLA4; amplify the engineered T cells as needed, test the quality and killing activity of the TILs and then transfuse them back the patients via systemic or local injections via standard protocol, and follow up closely to collect related parameters as needed; 4. To enhance the killing capability, tumor-noneffective TILs have also been genetically engineered to express various CARs targeting HER2/Mesothelin/Lewis-Y/PSCA/MUC1/ GPC3/AXL/EGFR/Claudin18.2/B7-H3/ROR1/GD2/AXL/Claudin6-DAP10 with knockdown of PD1/HPK1 as appropriate; 5. Evaluate the clinical results as needed.

Conditions

• Liver Cancer
• Lung Cancer
• Breast Cancer
• Colo-rectal Cancer
• Brain Tumor
• Solid Tumor, Adult
• PD1
• CTLA4

Interventions

Type	Name	Description
BIOLOGICAL	TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3	TILs and CAR-TILs injection: 1-10×10e7/kg cells for each treatment; 3 or more cycles.

Timeline

• Start date: 2021-01-01
• Primary completion: 2029-12-31
• Completion: 2035-01-01
• First posted: 2021-04-13
• Last updated: 2024-06-25

Locations

1 site across 1 country: China